SYMPOSIA
SYMPOSIA
SYMPOSIA
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
from triage to discharge.<br />
Key words: Crisis team, referral pathways, community care<br />
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S128-9<br />
Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org<br />
Poster Presentations<br />
[PP-014 Ref. No: 122<br />
Fluanxol and haloperidol efficacy evaluation in treatment of schizophrenic patients<br />
Elena Valzdorf<br />
Irkutsk Regional Psychoneurologic Dispensary, Irkutsk, Russia.<br />
E-mail: elenavalzdorf@yandex.ru<br />
Objective: The purpose of the research was to study the efficacy of Fluanxol in the treatment of schizophrenic patients compared with haloperidol.<br />
Method: Research subjects were 23 paroxysmal progredient schizophrenia patients, who were stationary examined. There were 18 men<br />
and 5 women among them, 6 patients of 16 to 20 years of age and 17 patients aged between 20 to 40 years.<br />
A clinical-psychopathological research method with a psychopharmacological approach was used.<br />
Results: Three groups of patients were picked out. The first group of 9 patients included patients with an acute and subacute exacerbation,<br />
Kandinski-Klerambo syndrome, acute sensitive delusions of grandeur, of influence, of persecution with imperative pseudo hallucinations,<br />
and open thought symptoms.<br />
The second group of 4 cases included patients with paraphrenia acute exacerbations, expansive delusions, and auditory pseudo<br />
hallucinations with oneric inclusions.<br />
In both groups the therapy began with traditional neuroleptics. Haloperidol depot 5 mg was prescribed intramuscularly once every 2<br />
weeks, but haloperidol intravenously from 5 to 10 mg a day. During 7-10 days of treatment, productive psychotic symptoms were reduced<br />
only through intensity in order to change preparation closed to atypical antipsychotic drug. So Fluanxol depot from 10-20 mg was<br />
prescribed intramuscularly once every 2 weeks and at the same time patients took it from 3 to 10 mg twice a day inside. During Fluanxol<br />
therapy, psychotic symptoms were reduced after 5-7 days of treatment.<br />
The third group of 10 people included less progredient schizophrenia patients with neurosis-like negative symptomatology. Haloperidol<br />
from, 1.5 to 5 mg a day inside for 3-4 weeks of treatment, didn’t have a positive effect on the negative symptoms. Fluanxol, from 1 to 3 mg<br />
twice a day inside for 7-12 days of treatment, caused a decrease in intensity or a complete reduction in negative symptomatology, so as<br />
mimics, mood, emotions were improved. This Fluanxol effect was shown by the two first groups having negative symptoms. Most patients<br />
took it without any corrector-preparation.<br />
Conclusion: Fluanxol is more effective in the treatment of schizophrenic patients.<br />
In comparison with haloperidol it decreased positive symptomatology more quickly, decreased or completely reduced negative<br />
symptoms and only in some cases caused drug side effects.<br />
Key words: Fluanxol, haloperidol, schizophrenia<br />
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S129<br />
[PP-015] Ref. No: 241<br />
Anorexia nervosa and cannabis abuse: A case report<br />
Semra Karayılan, Atila Erol<br />
Department of Psychiatry, Sakarya University School of Medicine, Sakarya, Turkey<br />
E-mail: skryln@gmail.com<br />
Rates of comorbidity are higher in patients with eating disorders and also the number of comorbid disorders is numerous. Most<br />
comorbidities associated with eating disorders are mood disorders, anxiety disorders, personality disorders, and substance use disorders.<br />
According to past research, there is a high rate of comorbidity of alcohol-substance abuse and eating disorders. Although the majority of<br />
studies in this area are focused on the use of alcohol, studies that have identified an association between illegal substance use and eating<br />
disorders are also available. In a study in the USA, the use of cannabis with anorexia nervosa (AN) and bulimia nervosa (BN) disorders is<br />
reported to be 6-7%. In Turkey, in a study that investigated the comorbidity of eating disorders and substance use, the use of alcohol and<br />
cannabis was reported in cases of BN, but the use of psychoactive substances and cannabis was not established in cases of AN. Among<br />
S129